Last reviewed · How we verify
Sevoflurane (Preconditioning)
Sevoflurane, when used as a preconditioning agent, activates cellular protective pathways that reduce ischemia-reperfusion injury by triggering mitochondrial ATP-sensitive potassium channels and anti-apoptotic signaling.
Sevoflurane, when used as a preconditioning agent, activates cellular protective pathways that reduce ischemia-reperfusion injury by triggering mitochondrial ATP-sensitive potassium channels and anti-apoptotic signaling. Used for Cardioprotection during cardiac surgery and ischemia-reperfusion injury prevention, Perioperative myocardial protection in high-risk surgical patients.
At a glance
| Generic name | Sevoflurane (Preconditioning) |
|---|---|
| Sponsor | University of Zurich |
| Drug class | Volatile anesthetic with cardioprotective preconditioning properties |
| Target | Mitochondrial ATP-sensitive potassium channels (mitoKATP); protein kinase C; endothelial nitric oxide synthase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Perioperative Medicine |
| Phase | FDA-approved |
Mechanism of action
Sevoflurane preconditioning involves brief exposure to the volatile anesthetic before a prolonged ischemic event, which primes cells to tolerate subsequent ischemia-reperfusion stress. This mechanism activates endogenous cardioprotective pathways including mitochondrial KATP channel opening, reactive oxygen species signaling, and inhibition of apoptosis. The effect reduces myocardial infarction size and improves functional recovery in cardiac and other tissues.
Approved indications
- Cardioprotection during cardiac surgery and ischemia-reperfusion injury prevention
- Perioperative myocardial protection in high-risk surgical patients
Common side effects
- Postoperative nausea and vomiting
- Hepatotoxicity (rare)
- Malignant hyperthermia (rare, genetic predisposition)
Key clinical trials
- Protection During Cardiac Surgery. (NA)
- Volatile Anesthetics in Cardiac Protection (PHASE4)
- Bleeding in Knee Arthroplasty After Preconditioning With Sevoflurane (NA)
- Impact if Desflurane Preconditioning on the Content of the Phospho-GSK-3b in the Rat's Neurons in the Model of I/R (PHASE4)
- Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC) (NA)
- Does Preconditioning Affects Other Organs in Patients Undergoing Open Heart Surgery ? (NA)
- Remote Preconditioning and Myocardial Protection (PHASE2)
- Impact of Variable Types of Preconditioning Upon the Inotrope Score in Adult Patients, Undergoing Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevoflurane (Preconditioning) CI brief — competitive landscape report
- Sevoflurane (Preconditioning) updates RSS · CI watch RSS
- University of Zurich portfolio CI